The Asia-Pacific Intrauterine devices (IUD’S) Market was worth $ 399.63 million in 2018 and estimated to reach $ 500.4 million by the end of 2023 with a growing potential of 4.60 %. Asia-Pacific accounts to hold the largest share in the market.
Intrauterine devices (IUDs) are contraceptive medical implants used to avoid pregnancies for a long-time period. It is injected into the uterus, and their primary aim is to inhibit the fertilization of the egg by causing changes, such as toxicity or thickening of the cervical mucus, thus inhibiting fertilization by a sperm. Mirena, Skyla and Paragard are some of the prominent brands available in the market. In Asia-Pacific region, most of the people are adopting to modern contraception such as oral pill, injectable contraceptives, condoms, implants, IUDs and male or female sterilisation. Modern contraceptive methods are more effective than traditional methods. For example, the rate of sterilisation fails less than 1 per cent for modern contraception’s in comparison to 25 per cent for periodic abstinence.
Asia-Pacific Intrauterine Device market is mainly driven by the factors such as Advancement in technical innovations, increasing prevalence of STD’S (Sexually transmitted diseases), instant health benefits other than birth control, increasing government initiatives to prevent unwanted abortions and pregnancies. The factors that are hindering the growth of the market are issues of Infertility, Religious and cultural opposition, Economic constraints, ectopic pregnancy, pelvic inflammatory infection, and Limited access to contraception.
The Asia-Pacific Intrauterine Devices market is broadly categorized based on product type into Hormonal intrauterine device and Copper intrauterine device. The largest share in the market is held by Hormonal IUD’S. Since, they have less risks compared to non-hormonal IUD’S.
Key players influencing the Asia-Pacific intrauterine devices market are Agile Therapeutics, Actavis PLC, ANI Pharmaceuticals, Inc, Bayer AG, Teva Pharmaceutical, Pfizer, Mylan laboratories, Besins HealthCare, Brecuro Medical, Effik International, Eurogine, HLL Lifecare, HRA Pharma, Lupin Pharmaceuticals, Ltd, Okamato Industries, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Hormonal Intrauterine Devices
5.1.2 Copper intrauterine Devices
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Agile Therapeutics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Actavis PLC
8.3 ANI Pharmaceuticals
8.4 Bayer
8.5 Teva Pharmaceutical
8.6 Besins HealthCare
8.7 Brecuro Medical
8.8 Effik International
8.9 Eurogine
8.10 HLL Lifecare
8.11 HRA Pharma
8.12 Lupin Pharmaceuticals
8.13 Okamato Industries
8.14 Pfizer
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market outlook and Investment oppurtunities
Appendix
a) List of Tables
b) List of Figures
